- Home
- SKWD vs VKTX Comparison
SKWD vs VKTX Comparison
Compare SKWD & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKWD
- VKTX
- Stock Information
- Founded
- SKWD 2007
- VKTX 2012
- Country
- SKWD United States
- VKTX United States
- Employees
- SKWD N/A
- VKTX N/A
- Industry
- SKWD Property-Casualty Insurers
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SKWD Finance
- VKTX Health Care
- Exchange
- SKWD Nasdaq
- VKTX Nasdaq
- Market Cap
- SKWD 2.4B
- VKTX 2.8B
- IPO Year
- SKWD 2023
- VKTX 2015
- Fundamental
- Price
- SKWD $57.33
- VKTX $26.01
- Analyst Decision
- SKWD Buy
- VKTX Buy
- Analyst Count
- SKWD 12
- VKTX 12
- Target Price
- SKWD $63.88
- VKTX $84.00
- AVG Volume (30 Days)
- SKWD 329.6K
- VKTX 2.9M
- Earning Date
- SKWD 08-04-2025
- VKTX 07-23-2025
- Dividend Yield
- SKWD N/A
- VKTX N/A
- EPS Growth
- SKWD 9.29
- VKTX N/A
- EPS
- SKWD 2.98
- VKTX N/A
- Revenue
- SKWD $1,213,759,000.00
- VKTX N/A
- Revenue This Year
- SKWD $18.33
- VKTX N/A
- Revenue Next Year
- SKWD $11.61
- VKTX N/A
- P/E Ratio
- SKWD $19.22
- VKTX N/A
- Revenue Growth
- SKWD 26.30
- VKTX N/A
- 52 Week Low
- SKWD $34.10
- VKTX $18.92
- 52 Week High
- SKWD $65.05
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- SKWD 40.75
- VKTX 44.01
- Support Level
- SKWD $56.96
- VKTX $25.61
- Resistance Level
- SKWD $59.79
- VKTX $30.17
- Average True Range (ATR)
- SKWD 1.90
- VKTX 1.43
- MACD
- SKWD -0.76
- VKTX -0.21
- Stochastic Oscillator
- SKWD 4.57
- VKTX 9.76
About SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that delivers commercial property and casualty products and solutions on a non-admitted and admitted basis. The firm has one reportable segment through which it offers a broad array of insurance coverages to several market niches. It operates multiple lines of business, including general liability, excess liability, professional liability, commercial auto, group accident, health, property, surety, and workers' compensation.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.